Arthritis in the Workplace
Arthritis is the most common cause of disability in the United States. Check out this Arthritis Today story on arthritis and blue collar workers:...
View ArticleClik here to view.
UNC arthritis study gets a break: $3.25M CDC grant
A long-running arthritis study at the University of North Carolina at Chapel Hill has been awarded a $3.25 million grant from the Centers for Disease Control and Prevention to follow up on patients...
View ArticleClik here to view.
Arthritis drug Vimovo’s slow sales are a pain to Pozen
If you only looked at Pozen‘s (NASDAQ:POZN) top and bottom lines from its third-quarter earnings, you might have missed a key detail affecting the pharmaceutical company’s financial performance....
View ArticleDe-Stressing the Holidays and Enjoying the Season More
We’re in the thick of it now. The thick of the holidays, that is. The season offers wonderful opportunities to connect with family and friends combined with a plethora of ways to amplify stress. For...
View ArticleClik here to view.
GSK licenses ChemoCentryx arthritis treatment to bolster drug pipeline
GlaxoSmithKline (NYSE:GSK) is strengthening its drug pipeline with an experimental arthritis treatment from drug partner ChemoCentryx. The pharmaceutical giant has exercised an option for an exclusive...
View ArticleClik here to view.
Cardinal Health launches infusion therapy tool for rheumatology practices
Pharmaceuticals distributor Cardinal Health (NYSE:CAH) has launched a web-based tool to help rheumatology practices better manage infusion therapy patients. Cardinal’s new InfusaTrack software is...
View ArticleClik here to view.
GSK grips arthritis compounds from drug partner Galapagos
GlaxoSmithKline (NYSE:GSK) is strengthening its prospects of developing a new arthritis treatment by licensing two anti-inflammatory compounds from drug partner Galapagos NV (OTC:GLPYY). Belgium-based...
View ArticleClik here to view.
How arthritis drug Vimovo shaped POZN’s strategy on its heart drug
Arthritis represents a large medical need but it is served by several products that carry gastrointestinal risks. Arthritis treatment Vimovo, developed as an alternative that’s easier on the stomach,...
View ArticleClik here to view.
CHTP’s arthritis drug fails phase 2; now everything rides on Northera
Chelsea Therapeutics‘ (NASDAQ:CHTP) rheumatoid arthritis treatment failed in phase 2 clinical trials and leaves the beleaguered drug developer to focus its remaining resources on an orphan drug...
View ArticleClik here to view.
Roche’s Actemra can now be used in earlier-stage arthritis treatment
(Reuters) - Roche Holding AG said U.S. regulators have widened the approved use of rheumatoid arthritis drug Actemra to include patients typically in earlier stages of treatment for the joint disease....
View ArticleClik here to view.
Roche’s rheumatoid arthritis treatment Actemra moves forward in Japan
ZURICH (Reuters) - Roche Holding AG's Japanese subsidiary Chugai said on Monday that Japanese health regulators have approved a new formulation of its rheumatoid arthritis drug Actemra. Japanese...
View ArticleClik here to view.
With a band of biotech collaborators, RuiYi sets sail developing new biologic...
The La Jolla, California, biotech formerly known as Anaphore is looking a little different these days. Under the leadership of former Fate Therapeutics CEO Paul Grayson, Anaphore changed its name to...
View ArticleClik here to view.
Synthetic cartilage implant designed to restore natural joint mechanics in...
With an ongoing clinical trial and a new investment, startup Cartiva Inc. is well on its way to bringing a less invasive, motion-preserving alternative to joint fusion to patients in the U.S. The...
View ArticleClik here to view.
Shock absorbers for the human body? Implant could help active patients avoid...
from Moximed Think shock absorbers for the human body. Moximed could help active and young patients who have osteoarthritis prolong the amount of time before total knee replacement. The Heyward,...
View ArticleClik here to view.
EU approves Novartis arthritis drug to treat children two and older
ZURICH (Reuters) - Novartis said on Tuesday its arthritis drug Ilaris was approved in the European Union to treat children aged two years and older. Novartis said Ilaris is already sold for treating...
View ArticleClik here to view.
Entrepreneur’s arthritic grandmother inspires a medtech fork + $9,500...
When Rise Assistive Devices CEO Vadim Gordin tried to buy his grandmother a fork she could use more easily, what he found were forks jammed into bicycle handles. He used his biomedical engineering...
View ArticleClik here to view.
Nektar Therapeutics pain drug for knee arthritis misses study goal
(Reuters) - Nektar Therapeutics said its experimental drug to treat chronic pain in patients with arthritis of the knee failed to meet its main goal in a mid-stage clinical trial. The drugmaker's...
View ArticleWant to solve your men’s health issue? Grow a mustache, join the Movember...
Doctor Mike Evans’ Youtube Channel is one of my favorites. Watching “23 1/2 hours” changed my perspective on how I should be treating my body. Now, he and Movember CEO Adam Garone (TED Talk here) have...
View ArticleClik here to view.
Healthcare design firm creates user-friendly auto-injector rheumatoid...
Aira, Cambridge Consultants’ auto-injector for rheumatoid arthritis patients A British healthcare design firm has come out with a new drug-delivery device to add to its innovative portfolio: an...
View ArticleClik here to view.
One-third of knee replacements deemed not necessary in arthritis study
NEW YORK (Reuters Health) - Judging by the symptoms of people with knee arthritis, one-third of knee replacement surgeries may be inappropriate, according to a new study. “We found that some patients...
View Article
